scholarly journals One‐year trends from the LANDMARC trial: A 3‐year, pan‐India, prospective, longitudinal study on the management and real‐world outcomes of type 2 diabetes mellitus

2021 ◽  
Author(s):  
Ashok K. Das ◽  
Sanjay Kalra ◽  
Shashank Joshi ◽  
Ambrish Mithal ◽  
Prasanna Kumar K. M. ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Longitudinal Study ◽  
Real World ◽  
Prospective Longitudinal Study ◽  
One Year ◽  
Prospective Longitudinal

Effect of Sodium Glucose Co-Transporter-2 Inhibition on the Aldosterone/Renin Ratio in Type 2 Diabetes Mellitus

2018 ◽  
Vol 51 (02) ◽  
pp. 91-99 ◽  
Author(s):  
Tomás Griffin ◽  
Md Islam ◽  
Liam Blake ◽  
Marcia Bell ◽  
Matthew Griffin ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Clinical Care ◽  
False Negative ◽  
Serum Triglycerides ◽  
Plasma Aldosterone Concentration ◽  
Prospective Longitudinal Study ◽  
Prospective Longitudinal

AbstractThe aldosterone to renin ratio (ARR) is recommended for case detection of primary aldosteronism (PA). Several factors including medications can undermine its diagnostic accuracy. The objective was to explore the effect of Sodium Glucose Co-Transporter-2 Inhibition on the ARR in patients with type 2 diabetes mellitus (T2DM) who were prescribed a Sodium Glucose Co-Transporter-2 Inhibitor (SGLT-2i) as part of routine clinical care. The primary outcomes were intra-individual changes in aldosterone, renin and ARR. Participants were recruited at routine diabetes outpatient visits as part of a prospective longitudinal study. Eligible participants were prescribed standard doses of empagliflozin and sampled at baseline (pre-SGLT-2i) and at their next routine outpatient visit (post-SGLT-2i). After a mean of 198 (±87) days on SGLT-2i treatment (n=20), there was a significant reduction in HbA1c, BMI, eGFR and serum triglycerides and a significant increase in serum creatinine and sodium. Compared with baseline, there was a significant increase in median direct renin concentration (mIU/l) [40.3 (6.2–249.5) vs. 70.2 (7.0, 551.0) (p=0.005)] and no significant change in median plasma aldosterone concentration (pmol/l) [296 (101, 685) vs. 273 (101, 794) (p=0.541)] with a significant reduction in median ARR (pmol/mIU) [6.9 (0.6–70.7) vs. 5.3 (0.2–39.3) (p=0.007)]. The proportion of participants with a screen positive ARR decreased from 20% (pre-SGLT-2i) to 5% (post-SGLT-2i) (p=0.248). Although performed in a relatively small cohort of medically complex patients, the study indicates that SGLT-2i therapy has the potential to cause false-negative screening for PA in the setting of T2DM. Future confirmatory studies should include patients with confirmed PA.

Real world data of Type 2 Diabetes Mellitus (T2DM) obese patients using another GLP1 receptor agonist (GLP1–RA) and switching to Semaglutide in Spain

2020 ◽  
Author(s):  
Jersy Cardenas ◽  
Gomez Nancy Sanchez ◽  
Sierra Poyatos Roberto Miguel ◽  
Luca Bogdana Luiza ◽  
Mostoles Naiara Modroño ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Real World ◽  
Receptor Agonist ◽  
Obese Patients ◽  
Real World Data ◽  
World Data

Promoters of and Barriers to Engagement in Type 2 Diabetes Mellitus (T2DM) Populations with Real-World Technological Interventions

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 660-P
Author(s):  
KEVIN R. DUVALL ◽  
ANJALI TRASY ◽  
ERIN MURRAY ◽  
ROBERT MILAM ◽  
TOBIAS SAYRE ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Real World ◽  
Technological Interventions
Sign in / Sign up

Export Citation Format

Share Document